Fig. 6
Anti-tumor effect of exoscFv/siLPCAT1 in vitro. (A) Western blot analysis of LPCAT1 protein expression in PC9 cells treated with exoscFv/siLPCAT1 or exoscFv/siNC. (B) The relative change in mRNA expression of LPCAT1 in PC9 cells treated with exoscFv/siLPCAT1 or exoscFv/siNC (Data were expressed as mean ± SD. n = 3). (C) CCK8 assay of PC9 cells treated with PBS, exoscFv, exoscFv/siLPCAT1 or exoscFv/siNC, Data were expressed as mean ± SD. n = 3. (D-E) Flow cytometry assay of the expression of ki67 in PC9 cells treated with PBS, exoscFv, exoscFv/siLPCAT1 or exoscFv/siNC, color legend shared with panel C. (F-G) Flow cytometry assay of PC9 cells staining with AnnexinV-FITC/PI after being treated with PBS, exoscFv, exoscFv/siLPCAT1 or exoscFv/siNC, color legend shared with panel C. *p < 0.05, **p < 0.01, ***p < 0.001